Pregabalin Solution
Product Images NDC 67877-457

16 FDA label images from Ascend Laboratories, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 67877-457). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ascend Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pregabalin-image (Pregabalin Image)

Pregabalin-image (Pregabalin Image)
The image shows a formula for calculating creatinine clearance (CLCr), involving age in years, weight in kilograms, serum creatinine in mg/dL, and a factor of 0.85 for female patients. This formula appears as part of clinical or pharmacokinetic information related to the Pregabalin oral solution.*
FDA Label Image

Pregabalin-structure (Pregabalin Structure)

Pregabalin-structure (Pregabalin Structure)
Chemical structure diagram of Pregabalin showing its molecular components, including amino and carboxyl functional groups. The diagram represents the active ingredient in the product labeled Pregabalin oral solution 20 mg/mL by Ascend Laboratories, LLC.*
FDA Label Image

Pregabalin-chart1.jpg (Pregabalin Chart1)

Pregabalin-chart1.jpg (Pregabalin Chart1)
A line graph comparing the percent improvement in pain from baseline against the percent of patients improved for different doses of Pregabalin (200 mg, 100 mg, 25 mg, each taken three times a day) and a placebo group. The graph shows how patient improvement varies with pain reduction percentages for each treatment.*
FDA Label Image

Pregabalin-chart2 (Pregabalin Chart2)

Pregabalin-chart2 (Pregabalin Chart2)
A line graph comparing the percent of patients improved versus percent improvement in pain from baseline. It shows two lines: one for Pregabalin 100 mg three times a day and one for placebo, with Pregabalin consistently showing a higher percentage of patient improvement across various pain improvement levels.*
FDA Label Image

Pregabalin-chart3 (Pregabalin Chart3)

Pregabalin-chart3 (Pregabalin Chart3)
A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at 75 mg, 150 mg, and 300 mg dosed twice daily, compared with placebo. The graph visually compares the efficacy across these doses and placebo in a clinical context.*
FDA Label Image

Pregabalin-chart4 (Pregabalin Chart4)

Pregabalin-chart4 (Pregabalin Chart4)
A graph depicting the percent of patients improved versus percent improvement in pain from baseline for Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The plot compares effectiveness in pain reduction across these three groups.*
FDA Label Image

Pregabalin-chart5 (Pregabalin Chart5)

Pregabalin-chart5 (Pregabalin Chart5)
This line graph depicts the percent of patients improved against the percent improvement in pain from baseline, comparing Pregabalin 100 mg and 50 mg taken three times a day with placebo. The graph illustrates the relationship between pain improvement percentages and patient response rates for the treatments.*
FDA Label Image

Pregabalin-figure-6new-a (Pregabalin Figure 6new A)

Pregabalin-figure-6new-a (Pregabalin Figure 6new A)
Bar chart comparing responder rates (%) across different dosages of Pregabalin in two studies (E1 and E3). The chart shows doses ranging from placebo to 600 mg/day with BID and TID regimens, displaying increased responder rates with higher doses, with statistical significance noted versus placebo.*
FDA Label Image

Pregabalin-chart7new-a (Pregabalin Chart7new A)

Pregabalin-chart7new-a (Pregabalin Chart7new A)
A line graph showing seizure reduction (median % change from baseline) plotted against dose (mg/day) for four studies labeled E1 BID, E2 TID, E3 BID, and E3 TID. Data points are marked with circles, squares, and triangles, with all showing significant p-values (≤0.0001 or 0.0007). The graph compares dose effects on seizure reduction with placebo noted at 0 dose.*
FDA Label Image

Pregabalin-figure-8-a (Pregabalin Figure 8 A)

Pregabalin-figure-8-a (Pregabalin Figure 8 A)
A bar chart showing responder rates in percentage for three groups: Placebo (22.6%), 2.5 mg/kg/day (29.1%), and 10 mg/kg/day (40.6%). The sample sizes (N) for each group are 93, 103, and 96 respectively.*
FDA Label Image

Pregabalin-figure-9-a (Pregabalin Figure 9 A)

Pregabalin-figure-9-a (Pregabalin Figure 9 A)
A line graph showing percent of patients improved plotted against percent improvement in pain from baseline. Four lines represent different groups: Pregabalin 600 mg daily dose, Pregabalin 450 mg daily dose, Pregabalin 300 mg daily dose, and placebo. The graph depicts comparative patient outcomes for these dosing groups over a range of pain improvement percentages.*
FDA Label Image

Pregabalin-chart10new-a (Pregabalin Chart10new A)

Pregabalin-chart10new-a (Pregabalin Chart10new A)
A Kaplan-Meier survival curve showing the estimated percentage of subjects without LTR (likely loss to recovery) over time in days. Two lines compare the Pregabalin group and the Placebo group, with Pregabalin represented by a solid line and Placebo by a dashed line. The vertical axis shows the percentage from 0% to 100%, and the horizontal axis shows the duration from 0 to 180 days.*
FDA Label Image

Pregabalin-chart10 (Pregabalin Chart10)

Pregabalin-chart10 (Pregabalin Chart10)
A line graph comparing the percent of subjects improved over a range of percent improvement from baseline to Week 12 between Pregabalin and placebo groups. The x-axis represents the percent improved from baseline, while the y-axis represents the percent of subjects improved. Two curves show that Pregabalin has higher improvement rates compared to placebo across the improvement scale.*
FDA Label Image

Pregabalin-chart11 (Pregabalin Chart11)

Pregabalin-chart11 (Pregabalin Chart11)
A line graph comparing the percent of subjects improved over time from baseline to week 16 using BOCF method for Pregabalin versus Placebo. The x-axis represents percent improvement from baseline to week 16, and the y-axis shows the percent of subjects improved. The graph depicts Pregabalin with a solid line and Placebo with a dotted line, showing higher improvement percentages for Pregabalin across the range.*
FDA Label Image

Pregabalin-cont-label (Pregabalin Cont Label)

Pregabalin-cont-label (Pregabalin Cont Label)
Label for Pregabalin 20 mg/mL oral solution by Ascend Laboratories, LLC. The label includes dosage strength, volume (16 fl oz/473 mL), manufacturer Alkem Laboratories Ltd. (India), distributor Ascend Laboratories (NJ), storage instructions at 25°C with allowed temperature excursions, and a barcode. It specifies Rx only and oral use only.*
FDA Label Image

Pregabalin-cart-label (Pregabalin Cart Label)

Pregabalin-cart-label (Pregabalin Cart Label)
Packaging label for Pregabalin Oral Solution 20 mg/mL, a 16 fl oz (473 mL) oral solution from Ascend Laboratories, LLC. The label includes storage instructions, a NDC number (67877-457-47), and specifies dispensing with the accompanying Medication Guide. Manufactured by Alkem Laboratories Ltd., Mumbai, India, and distributed by Ascend Laboratories in Bedminster, NJ.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.